Compass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at the highest dose levels and no dose-limiting toxicities observed.

Johnson Fistel, PLLP is investigating potential securities law violations by Compass Therapeutics following the disclosure that its lead drug candidate tovecimig failed to meet the overall survival secondary endpoint in the COMPANION-002 clinical trial. The company reported median overall survival of 8.9 months versus 9.4 months for the control arm, resulting in significant stock price decline. Investors who suffered losses are encouraged to contact the firm.

Compass Therapeutics will host a webcast on April 27, 2026 to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody combined with paclitaxel, in patients with advanced biliary tract cancer. The study has reached its prespecified event threshold of 80% overall survival events.

Compass Therapeutics announced participation in two healthcare investor conferences in December 2025, highlighting their ongoing clinical-stage oncology research focused on antibody-based therapeutics targeting tumor growth and immune system interactions.

Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.

Compass Therapeutics plans to raise approximately $120 million through a public offering of 33,290,000 common stock shares and pre-funded warrants at $3.00 per share, with the proceeds intended for research, clinical development, and corporate purposes.

Compass Therapeutics plans to launch an underwritten public offering of common stock and pre-funded warrants to fund research, clinical development, and commercial readiness preparations.

Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.

Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in September 2024, where it will present updates on its oncology-focused pipeline of antibody-based therapeutics.

Eliem Therapeutics announced the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. The new executives bring extensive experience in the pharmaceutical and biotechnology industries, which will help Eliem advance its pipeline of therapeutics for autoimmune-driven inflammatory diseases.

Compass Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present at the Wedbush PacGrow Healthcare Conference on August 13, 2024. The company is developing proprietary antibody-based therapeutics to treat multiple human diseases, with a focus on the relationship between angiogenesis, the immune system, and tumor growth.

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.